Skip to content
Screener

Nurix Therapeutics, Inc. NRIX Investing Cash Flow

Investing Cash Flow at other companies

Arvinas logo
ArvinasARVN
$13.7M-80.3%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$142.84M-394%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-$28.86M
Septerna, Inc. logo
Septerna, Inc.SEPN
-$23.82M-389%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$50.69M+272%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$35.35M-372%

Other financials

Income statement

See full
Revenue$9.0M-79.5%
Operating income-$94.2M-95.0%
Net income-$89.5M-106%
EPS (diluted)-$0.81-55.8%

Balance sheet

See full
Cash & equivalents$68.7M-19.4%
Total debt$58.1M+12.0%
Total equity$402.6M-10.0%
Total assets$535.5M-9.5%

Cash flow

See full
Operating cash flow-$96.6M-52.9%
CapEx$1.9M-27.6%
Free cash flow-$98.5M-49.6%

Valuation

See full
Market cap$2.62B+227%
Enterprise value$2.61B+240%
P/S71.2×+62.1×

Profitability

See full
Operating margin-982.4%-1,538pp
Net margin-928.4%-1,403pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-80.3%+113pp
Debt / equity0.1×0.0×
Current ratio6.3×-0.5×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026.

Filed
Apr 8, 2026, 6:03 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001549595-26-000025
Line itemThree Months Ended February 28, 2026Three Months Ended February 28, 2025
Purchases of marketable securities(255,934)(110,183)
Maturities of marketable securities133,153139,201
Purchases of property and equipment(1,045)(3,485)
Net cash provided by (used in) investing activities(123,826)25,533
Cash flows from financing activities
Proceeds from exercise of stock options375221
Proceeds from issuance of common stock under employee stock purchase plan1,5961,252
Proceeds from issuances of common stock in “at the market” financing, net of issuance costs18,004

Item 1. Financial Statements (Unaudited)

FAQ

What is Nurix Therapeutics, Inc.'s investing cash flow?
Nurix Therapeutics, Inc. (NRIX) reported investing cash flow of -$123.83M in Q4 2025.
How has Nurix Therapeutics, Inc.'s investing cash flow changed year-over-year?
Nurix Therapeutics, Inc.'s investing cash flow decreased by 585.0% year-over-year, from $25.53M to -$123.83M.
What is the long-term trend for Nurix Therapeutics, Inc.'s investing cash flow?
Over 2 years (2021 to 2025), Nurix Therapeutics, Inc.'s investing cash flow has grown at a 16.9% compound annual growth rate (CAGR), from -$108.25M to $147.85M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Nurix Therapeutics, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude